Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy
Shubrook, J.H.
Journal of Family Practice 67(8 Suppl): S49-S54
2018
ISSN/ISBN: 1533-7294 PMID: 30137054 Document Number: 695694
Document emailed within 1 workday
Related Documents
Scheen, A.é J.; Paquot, N. 2014: Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes Revue Medicale Suisse 10(439): 1549-1554Scheen, A.J. 2016: Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes Revue Medicale de Liege 71(3): 154-160
Shomali, M.E. 2009: Practical applications of therapy with a glucagon-like peptide-1 receptor agonist Journal of Family Practice 58(9 Suppl Treating): S35-S43
Kuritzky, L. 2006: Addition of basal insulin to oral antidiabetic agents: a goal-directed approach to type 2 diabetes therapy Medgenmed: Medscape General Medicine 8(4): 34
Xu, J.; Lin, S.; Yin, J. 2015: Effect of gastric bypass operation on expressions of adipic insulin receptor and insulin receptor substrate-1 in rats with type 2 diabetes mellitus Zhonghua Wei Chang Wai Ke Za Zhi 18(1): 65-68
Brunton, S.A.; White, J.R.; Renda, S.M. 2005: The role of basal insulin in type 2 diabetes management Journal of Family Practice Suppl: S1-S8
Ghosal, S.; Sinha, B.; Majumder, A.; Das, A.Kumar.; Singh, A.Kumar.; Ghoshdastidar, B.; Maji, D.; Goyal, G.; Mukherjee, J.Jyoti.; Gangopadhyay, K.Kumar.; John, M.; Chatterjee, S.; Jaggi, S.; Ray, S.; Majumdar, S.; Sharma, S.Kumar. 2017: Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?" Journal of the Association of Physicians of India 65(7): 51-62
Bogdanski, P.; Pupek-Musialik, D.; Dytfeld, J.; Jagodzinski, P.P.; Jablecka, A.; Kujawa, A.; Musialik, K. 2007: Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus International Journal of Clinical Pharmacology and Therapeutics 45(10): 563-567
Bu, S.; Guo, X.-H.; Yang, W.-Y.; Lu, G.-Z.; Yang, Z.-J.; Ren, T.-T.; Gao, Y. 2007: Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents regimen Zhonghua Yi Xue Za Zhi 87(44): 3115-3118
Clauser, E.; Assan, R. 1993: Insulin resistance and molecular abnormalities of the insulin receptor in type Ii diabetes Journees Annuelles de Diabetologie de l'Hotel-Dieu 1993: 23-36
Holman, R.R.; Steemson, J.; Turner, R.C. 1987: Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement Diabetic Medicine: a Journal of the British Diabetic Association 4(5): 457-462
Kalra, S.; Gupta, Y. 2016: A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus Jpma. Journal of the Pakistan Medical Association 66(3): 360-361
Wei, P.; Yang, Y.; Li, T.; Ding, Q.; Sun, H. 2015: A engineered Bifidobacterium longum secreting a bioative penetratin-Glucagon-like peptide 1 fusion protein enhances Glucagon-like peptide 1 absorption in the intestine Journal of Microbiology and Biotechnology 2015
Imachi, H.; Murao, K. 2012: Insulin, glucagon, insulin autoantibody (IAA), insulin receptor antibody Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 3): 442-445
Aoyama, N. 2007: Effect of combination therapy with angiotensin Ii type i receptor and aldosterone receptor blockers in heart failure Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 5): 145-149
Sumník, Z.; Venhácová, J.; Brázdová, L.; Skvor, J. 2008: Long-term improvement of fasting glycaemia after switching basal insulin from NPH to determir in children with type 1 diabetes: a 1-year multicentre study Casopis Lekaru Ceskych 147(8): 421-425
Mozdzan, M.ł; Mozdzan, M.; Loba, J.; Markuszewski, L.; Ruxer, J. 2006: Effect of short-term intensive insulin therapy on daily insulin requirement in poorly controlled type 2 diabetes patients Wiadomosci Lekarskie 59(3-4): 203-207
DeWitt, D.E.; Hirsch, I.B. 2003: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review JAMA 289(17): 2254-2264
Mizrahi, E.; Liberty, I.; Tsedek, I.; Harari, M.; Friger, M.; Sukenik, S. 2011: The influence of single immersion in Dead Sea water on glucose, insulin, cortisol and C-peptide levels in type 2 diabetes mellitus patients Harefuah 150(8): 646-649; 689, 688
Czyźyk, A.; Lawecki, J.; Strycek-Kaminska, D. 1981: Cholinergic regulation of insulin and glucagon secretion in healthy people and in patients with non-insulin dependent diabetes Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 36(2): 43-47